Exact Mass: 615.3228

Hypaconitine

C33H45NO10 (615.3043)

Hypaconitine is a diterpenoid. Hypaconitine is a natural product found in Aconitum japonicum, Aconitum firmum, and other organisms with data available. Annotation level-1 Hypaconitine, an active and highly toxic constituent derived from Aconitum species, is widely used to treat rheumatism. IC50 value: Target: In vitro: The present study investigated the metabolism of hypaconitine in vitro using male human liver microsomes. The primary contributors toward HA metabolism were CYP3A4 and 3A5, with secondary contributions by CYP2C19, 2D6 and CYP2E1 [1]. In vivo: Hypaconitine, an active and highly toxic constituent derived from Aconitum species, is widely used to treat rheumatism. IC50 value: Target: In vitro: The present study investigated the metabolism of hypaconitine in vitro using male human liver microsomes. The primary contributors toward HA metabolism were CYP3A4 and 3A5, with secondary contributions by CYP2C19, 2D6 and CYP2E1 [1]. In vivo:

Paromomycin

C23H45N5O14 (615.2963)

Paromomycin is only found in individuals that have used or taken this drug. It is an oligosaccharide antibiotic produced by various streptomyces. [PubChem]Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA. Bacterial proteins are synthesized by ribosomal RNA complexes which are composed of 2 subunits, a large subunit (50s) and small (30s) subunit, which forms a 70s ribosomal subunit. tRNA binds to the top of this ribosomal structure. Paramomycin binds to the A site, which causes defective polypeptide chains to be produced. Continuous production of defective proteins eventually leads to bacterial death. A - Alimentary tract and metabolism > A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents > A07A - Intestinal antiinfectives > A07AA - Antibiotics D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic KEIO_ID P126

6-hydroxyneomycin C

C23H45N5O14 (615.2963)

Neomycin F

C23H45N5O14 (615.2963)

Paromomycin I

C23H45N5O14 (615.2963)

D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents

Hypaconitine

C33H45NO10 (615.3043)

Gedatolisib

C32H41N9O4 (615.3281)

C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively[1]. Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2[2]. Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively[1]. Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2[2].

PC(2:0/PGJ2)

C30H50NO10P (615.3172)

PC(2:0/PGJ2) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/PGJ2), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin J2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(PGJ2/2:0)

C30H50NO10P (615.3172)

PC(PGJ2/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(PGJ2/2:0), in particular, consists of one chain of one Prostaglandin J2 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

Bu 2659B

C23H45N5O14 (615.2963)

Hexosyl LPE 16:0

C27H54NO12P (615.3383)

Annotation level-3

16-Epipyrojesaconitine

C33H45NO10 (615.3043)

(32S,52S)-31-[N-(N,N-dimethyl-L-isoleucyl)-L-phenylalanyl]-(32rH,33tH)-2-oxa-7-aza-1(1,4)-benzena-3(3,2),5(1,2)-dipyrrolidina-cyclononaphan-8c-ene-4,6-dione|Hysodricanin-A|Hysodricanine A|hysodricanine-A

C35H45N5O5 (615.3421)

balfourine

C33H45NO10 (615.3043)

M-PLM-B

C29H46NO11P (615.2808)

destruxin E2 chlorohydrin

C28H46ClN5O8 (615.3035)

Pseudaconitin

C34H49NO9 (615.3407)

Trp Leu Val Ala Asn

C30H45N7O7 (615.338)

Leu Asp Gln Gln Val

C26H45N7O10 (615.3228)

Val Asn Leu Arg Thr

C26H49N9O8 (615.3704)

Val Arg Gln Val Asp

C25H45N9O9 (615.334)

Glu Gly Leu Arg Gln

C25H45N9O9 (615.334)

Glu Glu Val Leu Ile

C28H49N5O10 (615.3479)

Glu Arg Arg Arg

C23H45N13O7 (615.3565)

Phe Phe Phe Arg

C33H41N7O5 (615.3169)

Phe Phe Arg Phe

C33H41N7O5 (615.3169)

Phe Met Arg Tyr

C29H41N7O6S (615.2839)

Phe Met Tyr Arg

C29H41N7O6S (615.2839)

Phe Arg Phe Phe

C33H41N7O5 (615.3169)

Phe Arg Met Tyr

C29H41N7O6S (615.2839)

Phe Arg Tyr Met

C29H41N7O6S (615.2839)

Phe Tyr Met Arg

C29H41N7O6S (615.2839)

Phe Tyr Arg Met

C29H41N7O6S (615.2839)

Lys Pro Trp Trp

C33H41N7O5 (615.3169)

Lys Trp Pro Trp

C33H41N7O5 (615.3169)

Lys Trp Trp Pro

C33H41N7O5 (615.3169)

Met Phe Arg Tyr

C29H41N7O6S (615.2839)

Met Phe Tyr Arg

C29H41N7O6S (615.2839)

Met Arg Phe Tyr

C29H41N7O6S (615.2839)

Met Arg Tyr Phe

C29H41N7O6S (615.2839)

Met Tyr Phe Arg

C29H41N7O6S (615.2839)

Met Tyr Arg Phe

C29H41N7O6S (615.2839)

Pro Lys Trp Trp

C33H41N7O5 (615.3169)

Pro Gln Trp Trp

C32H37N7O6 (615.2805)

Pro Trp Lys Trp

C33H41N7O5 (615.3169)

Pro Trp Gln Trp

C32H37N7O6 (615.2805)

Pro Trp Trp Lys

C33H41N7O5 (615.3169)

Pro Trp Trp Gln

C32H37N7O6 (615.2805)

Gln Pro Trp Trp

C32H37N7O6 (615.2805)

Gln Trp Pro Trp

C32H37N7O6 (615.2805)

Gln Trp Trp Pro

C32H37N7O6 (615.2805)

Arg Glu Arg Arg

C23H45N13O7 (615.3565)

Arg Phe Phe Phe

C33H41N7O5 (615.3169)

Arg Phe Met Tyr

C29H41N7O6S (615.2839)

Arg Phe Tyr Met

C29H41N7O6S (615.2839)

Arg Met Phe Tyr

C29H41N7O6S (615.2839)

Arg Met Tyr Phe

C29H41N7O6S (615.2839)

Arg Arg Glu Arg

C23H45N13O7 (615.3565)

Arg Arg Arg Glu

C23H45N13O7 (615.3565)

Arg Arg Val Trp

C28H45N11O5 (615.3605)

Arg Arg Trp Val

C28H45N11O5 (615.3605)

Arg Val Arg Trp

C28H45N11O5 (615.3605)

Arg Val Trp Arg

C28H45N11O5 (615.3605)

Arg Trp Arg Val

C28H45N11O5 (615.3605)

Arg Trp Val Arg

C28H45N11O5 (615.3605)

Arg Tyr Phe Met

C29H41N7O6S (615.2839)

Arg Tyr Met Phe

C29H41N7O6S (615.2839)

Val Arg Arg Trp

C28H45N11O5 (615.3605)

Val Arg Trp Arg

C28H45N11O5 (615.3605)

Val Trp Arg Arg

C28H45N11O5 (615.3605)

Trp Lys Pro Trp

C33H41N7O5 (615.3169)

Trp Lys Trp Pro

C33H41N7O5 (615.3169)

Trp Pro Lys Trp

C33H41N7O5 (615.3169)

Trp Pro Gln Trp

C32H37N7O6 (615.2805)

Trp Pro Trp Lys

C33H41N7O5 (615.3169)

Trp Pro Trp Gln

C32H37N7O6 (615.2805)

Trp Gln Pro Trp

C32H37N7O6 (615.2805)

Trp Gln Trp Pro

C32H37N7O6 (615.2805)

Trp Arg Arg Val

C28H45N11O5 (615.3605)

Trp Arg Val Arg

C28H45N11O5 (615.3605)

Trp Val Arg Arg

C28H45N11O5 (615.3605)

Trp Trp Lys Pro

C33H41N7O5 (615.3169)

Trp Trp Pro Lys

C33H41N7O5 (615.3169)

Trp Trp Pro Gln

C32H37N7O6 (615.2805)

Trp Trp Gln Pro

C32H37N7O6 (615.2805)

Tyr Phe Met Arg

C29H41N7O6S (615.2839)

Tyr Phe Arg Met

C29H41N7O6S (615.2839)

Tyr Met Phe Arg

C29H41N7O6S (615.2839)

Tyr Met Arg Phe

C29H41N7O6S (615.2839)

Tyr Arg Phe Met

C29H41N7O6S (615.2839)

Tyr Arg Met Phe

C29H41N7O6S (615.2839)

VRQVD

C25H45N9O9 (615.334)

QVKEL

C27H49N7O9 (615.3592)

LRTQV

C26H49N9O8 (615.3704)

Am-Hex-LPE 16:0

C27H54NO12P (615.3383)

Am-Hex-LPE 32:0

C27H54NO12P (615.3383)

Boc-Val-Leu-Lys-AMC acetate salt

C32H49N5O7 (615.3632)

LEUCINE ENKEPHALIN ACETATE SALT

C30H41N5O9 (615.2904)

3-[7-[2-(Cyclopropylmethoxy)-6-[(4-methoxyphenyl)methoxy]phenyl]-1,4-dihydro-2-oxo-2H-pyrido[2,3-d][1,3]oxazin-5-yl]-1-piperidinecarboxylic acid tert-butyl ester

C35H41N3O7 (615.2944)

3-[2-[4-[4-fluoro-2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]benzoyl]piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one

C35H39F2N5O3 (615.3021)

Gedatolisib

C32H41N9O4 (615.3281)

C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively[1]. Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2[2]. Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively[1]. Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2[2].

PC(2:0/PGJ2)

C30H50NO10P (615.3172)

PC(PGJ2/2:0)

C30H50NO10P (615.3172)

primary FDCC(1-)

C34H39N4O7- (615.2819)

N-[(3R,9S,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C33H49N3O6S (615.3342)

1-[[(2R,3S)-9-[[(cyclohexylamino)-oxomethyl]amino]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea

C35H45N5O5 (615.3421)

1-[[(2R,3R)-9-[[(cyclohexylamino)-oxomethyl]amino]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea

C35H45N5O5 (615.3421)

1-[[(2S,3S)-9-[[(cyclohexylamino)-oxomethyl]amino]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea

C35H45N5O5 (615.3421)

1-[[(2R,3S)-9-[[(cyclohexylamino)-oxomethyl]amino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea

C35H45N5O5 (615.3421)

1-[[(2S,3S)-9-[[(cyclohexylamino)-oxomethyl]amino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea

C35H45N5O5 (615.3421)

N-[(3R,9S,10S)-9-[[benzoyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C36H45N3O6 (615.3308)

N-[(3R,9R,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C33H49N3O6S (615.3342)

N-[(3S,9R,10R)-9-[[benzoyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C36H45N3O6 (615.3308)

N-[(3S,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-2-phenylacetamide

C37H49N3O5 (615.3672)

N-[(3S,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C33H49N3O6S (615.3342)

N-[(3S,9R,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C33H49N3O6S (615.3342)

N-[(3R,9R,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C33H49N3O6S (615.3342)

N-[(3R,9R,10S)-9-[[benzoyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C36H45N3O6 (615.3308)

N-[(3S,9S,10R)-9-[[benzoyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C36H45N3O6 (615.3308)

N-[(3S,9S,10S)-9-[[benzoyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C36H45N3O6 (615.3308)

1-[[(2R,3R)-9-[[(cyclohexylamino)-oxomethyl]amino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea

C35H45N5O5 (615.3421)

N-[(3R,9S,10S)-9-[[benzoyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C36H45N3O6 (615.3308)

N-[(3R,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C33H49N3O6S (615.3342)

N-[(3R,9R,10S)-9-[[benzoyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C36H45N3O6 (615.3308)

N-[(3S,9R,10R)-9-[[benzoyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C36H45N3O6 (615.3308)

N-[(3R,9R,10R)-9-[[benzoyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C36H45N3O6 (615.3308)

N-[(3S,9S,10R)-9-[[benzoyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C36H45N3O6 (615.3308)

N-[(3S,9R,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C33H49N3O6S (615.3342)

N-[(3S,9S,10S)-9-[[benzoyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C36H45N3O6 (615.3308)

N-[(3S,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-2-phenylacetamide

C37H49N3O5 (615.3672)

N-[(3R,9S,10R)-9-[[benzoyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C36H45N3O6 (615.3308)

N-[(3S,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C33H49N3O6S (615.3342)

N-[(3R,9S,10R)-9-[[benzoyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C36H45N3O6 (615.3308)

N-[(3S,9R,10S)-9-[[benzoyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C36H45N3O6 (615.3308)

N-[(3R,9R,10R)-9-[[benzoyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C36H45N3O6 (615.3308)

N-[(3S,9R,10S)-9-[[benzoyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzamide

C36H45N3O6 (615.3308)

N-[(3R,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-2-phenylacetamide

C37H49N3O5 (615.3672)

(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[[(2R,3S,4R,5R)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[[(3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)-3-oxolanyl]oxy]oxane-3,4-diol

C23H45N5O14 (615.2963)

(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2S,3S,5R,6S)-3,5-diamino-2-[(3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol

C23H45N5O14 (615.2963)

5-aminopentyl beta-D-glucopyranosyl-(1->3)-2-O-acetyl-6-deoxy-alpha-L-talopyranosyl-(1->3)-beta-D-glucopyranoside

C25H45NO16 (615.2738)

(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5R)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol

C23H45N5O14 (615.2963)

SHexCer 21:0;3O

C27H53NO12S (615.3288)

Lnaps 6:0/N-18:4

C30H50NO10P (615.3172)

Lnaps 20:4/N-4:0

C30H50NO10P (615.3172)

Lnaps 22:4/N-2:0

C30H50NO10P (615.3172)

Lnaps 18:4/N-6:0

C30H50NO10P (615.3172)

Lnaps 2:0/N-22:4

C30H50NO10P (615.3172)

Lnaps 4:0/N-20:4

C30H50NO10P (615.3172)

2-amino-3-[[3-butanoyloxy-2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C30H50NO10P (615.3172)

2-amino-3-[[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-octanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C30H50NO10P (615.3172)

2-amino-3-[[3-hexanoyloxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C30H50NO10P (615.3172)

3-[[3-acetyloxy-2-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxy-2-aminopropanoic acid

C30H50NO10P (615.3172)

(2R,3R,4S,5S,6S)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5R)-5-[(1S,2S,3R,5S,6R)-3,5-diamino-2-[(2R,3S,4S,5R,6S)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol

C23H45N5O14 (615.2963)

Paromomycin

C23H45N5O14 (615.2963)

An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis. A - Alimentary tract and metabolism > A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents > A07A - Intestinal antiinfectives > A07AA - Antibiotics D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic

PC O-23:5;O2

C31H54NO9P (615.3536)

PC P-16:1/7:3;O2

C31H54NO9P (615.3536)

PC 16:1/7:3;O

C31H54NO9P (615.3536)

PC 18:3/5:1;O

C31H54NO9P (615.3536)

PC 18:4/4:1;O2

C30H50NO10P (615.3172)

PC 22:5;O2

C30H50NO10P (615.3172)

PC 23:4;O

C31H54NO9P (615.3536)

LNAPE 26:4;O

C31H54NO9P (615.3536)

PE O-25:6;O3

C30H50NO10P (615.3172)

PE O-26:5;O2

C31H54NO9P (615.3536)

PE P-18:1/7:4;O3

C30H50NO10P (615.3172)

PE P-18:1/8:3;O2

C31H54NO9P (615.3536)

PE 14:1/12:3;O

C31H54NO9P (615.3536)

PE 16:1/9:4;O2

C30H50NO10P (615.3172)

PE 18:1/8:3;O

C31H54NO9P (615.3536)

PE 18:2/7:3;O2

C30H50NO10P (615.3172)

PE 18:3/7:2;O2

C30H50NO10P (615.3172)

PE 18:3/8:1;O

C31H54NO9P (615.3536)

PE 20:2/6:2;O

C31H54NO9P (615.3536)

PE 20:4/5:1;O2

C30H50NO10P (615.3172)

PE 25:5;O2

C30H50NO10P (615.3172)

PE 26:4;O

C31H54NO9P (615.3536)

LNAPS 23:5;O

C29H46NO11P (615.2808)

LNAPS 24:4

C30H50NO10P (615.3172)

PS O-24:5;O

C30H50NO10P (615.3172)

PS P-16:1/8:3;O

C30H50NO10P (615.3172)

PS P-18:1/6:3;O

C30H50NO10P (615.3172)

PS 18:4/5:1;O

C29H46NO11P (615.2808)

PS 23:5;O

C29H46NO11P (615.2808)

PS 20:3/4:1

C30H50NO10P (615.3172)

PS 20:4/4:0

C30H50NO10P (615.3172)

PS 22:4/2:0

C30H50NO10P (615.3172)

PS 24:4

C30H50NO10P (615.3172)

ST 21:2;O8;HexNAc

C29H45NO13 (615.2891)

ST 22:1;O7;HexNAc

C30H49NO12 (615.3255)

ST 23:0;O6;HexNAc

C31H53NO11 (615.3618)

ST 25:6;O5;HexNAc

C33H45NO10 (615.3043)

ST 26:5;O4;HexNAc

C34H49NO9 (615.3407)

ST 28:3;O7;Tau

C30H49NO10S (615.3077)

ST 29:2;O6;Tau

C31H53NO9S (615.3441)

(2r,3s,4r,5r,6s,8s,13r,14r,16s,17s,18r)-11-ethyl-5,14-dihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-7-oxo-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl 4-methoxybenzoate

C33H45NO10 (615.3043)

(2r,3s,4r,5r,6r)-5-amino-6-{[(2r,3s,4r,5s)-5-{[(1r,2r,3s,5r,6s)-3-amino-2-{[(2r,3r,4r,5s,6r)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-5,6-dihydroxycyclohexyl]oxy}-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}-2-(aminomethyl)oxane-3,4-diol

C23H45N5O14 (615.2963)

12-hydroxy-8-(2-hydroxypropan-2-yl)-6-methoxy-2,3,23,23,25,25-hexamethyl-7,24-dioxa-31-azaoctacyclo[15.14.0.0²,¹⁵.0³,¹².0⁶,¹¹.0¹⁸,³⁰.0²⁰,²⁸.0²²,²⁷]hentriaconta-1(17),10,18,20(28),22(27),29-hexaen-9-one

C38H49NO6 (615.356)

(1s,2r,3r,4r,5s,8r,9r,10r,13r,14r,16s,17s,18r)-11-ethyl-5,8,14-trihydroxy-16,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-6-en-4-yl 3,4-dimethoxybenzoate

C33H45NO10 (615.3043)

(2s,3r,4s,5s,6r)-5-amino-6-{[(2r,3s,4r,5s)-5-{[(1r,2r,3s,5r,6s)-3-amino-2-{[(2r,3r,4r,5s,6r)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-5,6-dihydroxycyclohexyl]oxy}-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}-2-(aminomethyl)oxane-3,4-diol

C23H45N5O14 (615.2963)

11-ethyl-5,8,14-trihydroxy-16,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-6-en-4-yl 3,4-dimethoxybenzoate

C33H45NO10 (615.3043)

5,7,11,18,22,29,33-heptahydroxy-1,4,7,12,18,23,29-heptaazacyclotritriaconta-1(33),4,11,22-tetraene-8,19,30-trione

C26H45N7O10 (615.3228)

(1s,2r,3r,4s,5r,8r,9r,10r,13r,14r,16s,17s,18r)-4-(2,3-dimethoxyphenyl)-11-ethyl-5,14-dihydroxy-16,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate

C34H49NO9 (615.3407)

11-ethyl-5-hydroxy-6,8,16,18-tetramethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl 4-methoxybenzoate

C34H49NO9 (615.3407)

(2s,3r,6s,8r,12s,15s)-12-hydroxy-8-(2-hydroxypropan-2-yl)-6-methoxy-2,3,23,23,25,25-hexamethyl-7,24-dioxa-31-azaoctacyclo[15.14.0.0²,¹⁵.0³,¹².0⁶,¹¹.0¹⁸,³⁰.0²⁰,²⁸.0²²,²⁷]hentriaconta-1(17),10,18,20(28),22(27),29-hexaen-9-one

C38H49NO6 (615.356)

(5r,6s,8r,13s)-8-(acetyloxy)-11-ethyl-5,7-dihydroxy-6,13,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl benzoate

C33H45NO10 (615.3043)

(1s,4r,5s,23s,26s,30r)-6,26-dihydroxy-4,5,13,13,15,15,31,31-octamethyl-14,32,33-trioxa-7-azaoctacyclo[28.2.1.0¹,²⁷.0⁴,²⁶.0⁵,²³.0⁸,²⁰.0¹⁰,¹⁸.0¹¹,¹⁶]tritriaconta-6,8(20),9,11(16),18,27-hexaene-21,29-dione

C37H45NO7 (615.3196)

(2r,3s,4r,5r,6r)-5-amino-6-{[(1r,2r,3s,4r,6s)-6-amino-2-{[(2s,3r,4s,5r)-4-{[(2r,3s,4s,5r,6r)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3,4-dihydroxycyclohexyl]oxy}-2-(aminomethyl)oxane-3,4-diol

C23H45N5O14 (615.2963)

6,26-dihydroxy-4,5,13,13,15,15,31,31-octamethyl-14,32,33-trioxa-7-azaoctacyclo[28.2.1.0¹,²⁷.0⁴,²⁶.0⁵,²³.0⁸,²⁰.0¹⁰,¹⁸.0¹¹,¹⁶]tritriaconta-6,8(20),9,11(16),18,27-hexaene-21,29-dione

C37H45NO7 (615.3196)

(2r,3s,4r,5r,6r,8s,13r,14r,16s,17s,18r)-11-ethyl-5,14-dihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-7-oxo-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl 4-methoxybenzoate

C33H45NO10 (615.3043)

(1r,2s,5s,6s,8r,9s,10r,12s,15r,16s,25r,27s,28r)-15,16,33,33-tetramethyl-24-methylidene-10-(prop-1-en-2-yl)-7,11,32-trioxa-18-azadecacyclo[25.4.2.0²,¹⁶.0⁵,¹⁵.0⁶,⁸.0⁶,¹².0¹⁷,³¹.0¹⁹,³⁰.0²²,²⁹.0²⁵,²⁸]tritriaconta-17(31),19,21,29-tetraene-2,5,9,28-tetrol

C37H45NO7 (615.3196)

(2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-{[(2r,3r,4r,5s)-5-{[(1r,2r,3s,5r,6s)-3,5-diamino-2-{[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-hydroxycyclohexyl]oxy}-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}oxane-3,4-diol

C23H45N5O14 (615.2963)

(1s,2r,3r,4r,5r,6s,7s,8s,9r,10r,13s,16s,17r,18s)-8-(acetyloxy)-5,7-dihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl benzoate

C33H45NO10 (615.3043)

(1s,4r,5s,16s,23s,26s,30r)-6,26-dihydroxy-4,5,13,13,15,15,31,31-octamethyl-14,32,33-trioxa-7-azaoctacyclo[28.2.1.0¹,²⁷.0⁴,²⁶.0⁵,²³.0⁸,²⁰.0¹⁰,¹⁸.0¹¹,¹⁶]tritriaconta-6,8(20),9,11,18,27-hexaene-21,29-dione

C37H45NO7 (615.3196)

(2s,3s,5r,8r,13s,17s)-8-(acetyloxy)-5,7-dihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl benzoate

C33H45NO10 (615.3043)

4-(2,3-dimethoxyphenyl)-11-ethyl-5,14-dihydroxy-16,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate

C34H49NO9 (615.3407)

(2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-{[(2r,3s,4r)-5-{[(1r,3s,5r,6s)-3,5-diamino-2-{[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-hydroxycyclohexyl]oxy}-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}oxane-3,4-diol

C23H45N5O14 (615.2963)

6,26-dihydroxy-4,5,13,13,15,15,31,31-octamethyl-14,32,33-trioxa-7-azaoctacyclo[28.2.1.0¹,²⁷.0⁴,²⁶.0⁵,²³.0⁸,²⁰.0¹⁰,¹⁸.0¹¹,¹⁶]tritriaconta-6,8(20),9,11,18,27-hexaene-21,29-dione

C37H45NO7 (615.3196)

15,16,33,33-tetramethyl-24-methylidene-10-(prop-1-en-2-yl)-7,11,32-trioxa-18-azadecacyclo[25.4.2.0²,¹⁶.0⁵,¹⁵.0⁶,⁸.0⁶,¹².0¹⁷,³¹.0¹⁹,³⁰.0²²,²⁹.0²⁵,²⁸]tritriaconta-17(31),19,21,29-tetraene-2,5,9,28-tetrol

C37H45NO7 (615.3196)